
VEXTF
Healthcare · Drug Manufacturers - Specialty & Generic · $32.2M market cap
$0.1410-0.00 (-2.8%)Nov 13, 1:59 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 21, 2026 | Before the open | -0.01 | 0.00 | +100.0% |
| Nov 20, 2025 | Before the open | -0.01 | -0.01 | 0.0% |
| Aug 20, 2025 | Before the open | -0.01 | -0.01 | 0.0% |
| May 21, 2025 | Before the open | -0.01 | -0.00 | +63.0% |
| Nov 21, 2024 | Before the open | -0.01 | -0.01 | 0.0% |
| Aug 20, 2024 | Before the open | -0.01 | -0.01 | 0.0% |
| May 29, 2024 | Before the open | 0.00 | -0.01 | — |
| Nov 28, 2023 | Before the open | -0.01 | -0.01 | 0.0% |
| Aug 24, 2022 | After the close | 0.00 | 0.02 | — |
| Apr 20, 2022 | Before the open | 0.01 | 0.01 | 0.0% |
| Nov 18, 2021 | Before the open | 0.01 | 0.01 | 0.0% |
| Aug 24, 2021 | Before the open | 0.01 | 0.01 | 0.0% |
Vext Science, Inc., through its subsidiaries, engages in integrated cannabis operations in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, edibles, and extracts. The company also engages in the retail dispensary activities; and wholesale distribution of…